Biomarker ID 2318 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2318 |
| Biomarker | CSTB |
| Biomarker Name/Symbol (given in Publication) | CSTB |
| Biomolecule | Protein and RNAs |
| Subject | Human |
| Degree of Validity | CSTB and AFP in combination might be a potential marker for diagnosing HCC and validated on independent dataset |
| Experimental Condition | HCC v/s cirrhosis/healthy/non-tumor HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upegulated in HCC than non-tumor |
| Level of significance | p < 0.05 |
| Source | Serum |
| PMID | 18281540 |
| Type of Biomarker | Diagnostic |
| Pathway | Protease inhibitor |
| Cohort | Normal healthy subjects (group 1, n = 52) and patients with noncirrhotic chronic hepatitis (group 2, n = 53), cirrhosis (group 3, n = 43), and HCC (group 4, n = 62); HCC cell lines, including HepG2, Hep3B, PLC/PRF/5, Huh7, and SK-HEP-1 cells, and immortalized epithelial cell lines, such as THLE-3 an |
| Sensitivity | 85.50% |
| Specificity | 53.10% |
| Accuracy | NA |
| AUC | 0.75 |
| Disease | HCC v/s cirrhosis/healthy/non-tumor HCC |
| Year of Publication | 2008 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |